Rimonabant Report - News about the diet drug rimonabant

RimonabantReport

Your INDEPENDENT source of news and reviews about the new diet drug rimonabant

This news site is NOT affiliated with NOR endorsed by Sanofi-Aventis, which markets rimonabant as Acomplia®

What Is Rimonabant?

What Studies Are Underway?

What Are the Pros & Cons?

Free Email

	The Rimonabant Report - News About Diet Drugs
	Welcome to the Rimonabant Report, where you can obtain the latest news about the launch of the Sanofi-Aventis anti-obesity drug Acomplia® in countries around the world -- as well as news of efforts by several Indian pharmaceutical companies to market generic versions of rimonabant. Whatever the name, rimonabant has been hailed by some doctors on the basis of study results as potentially a major breakthrough in treating obesity. Some 200,000 Europeans are now taking Acomplia. However, Sanofi's efforts to market rimonabant in the U.S. as Zimulti have been indefinitely delayed by concerns over depression and other side-effects. The Rimonabant Report, updated daily, will provide the latest news and reviews related to development and sale of rimonabant.
	Rimonabant News for May 2008 --News About Diet Drugs
	CT Scans Confirm Rimonabant Reduces Dangerous Abdominal Obesity
	Rimonabant News for April 2008 --News About Diet Drugs
	Rimonabant Disappoints in Heart Study; Side Effects Also an Issue
	Rimonabant News for March 2008 --News About Diet Drugs
	Diet Pill Taranabant Effective at Much Lower Dose Than Rimonabant Diet Drug Rimonabant (Acomplia) Gets Boost From British Health Panel Rimonabant May Cause Depression by Blocking TRPV1 Receptor in Brain Report: Taranabant Side-Effect Profile May Be Similar to Rimonabant Diet Drug Rimonabant May Help Block Development of Alcoholic Fatty Liver Sanofi's Acomplia Again Turned Down for Insurance Coverage in Germany Pfizer Lagging Behind Merck in Developing Competitor to Rimonabant
	Rimonabant News for February 2008 --News About Diet Drugs
	Are Lagging Acomplia Sales Being Hurt by Generic Rimonabant?
	Rimonabant News for January 2008 --News About Diet Drugs
	Will Diet Drug Taranabant Be This Year's Rimonabant?
	Rimonabant News for December 2007--News About Diet Drugs
	Merck on Track to File for FDA Approval of Diet Drug Taranabant in 2008 UK Panel Says Inclined 'Not to Recommend' Diet Pill Rimonabant for NHS
	Rimonabant News for November 2007--News About Diet Drugs
	Study Links Diet Drug Rimonabant to 'Severe Adverse Psychiatric Events' Study: Rimonabant Weight Loss 'Modest' and Safe-Effects Are Concern Class Action Lawsuit Filed Against Sanofi Over Acomplia (Rimonabant) Sanofi Allowed to Inform Patients Taking Acomplia It Aids Glucose Control Acomplia Sales Disappoint; No Major Improvement Seen Until 2009
	Rimonabant News for October 2007--News About Diet Drugs
	Taranabant Yields Encouraging Results With 'Generally Mild' Side-Effects First Official Report on Taranabant -- Rimonabant Competitor -- Due Oct. 24
	Rimonabant News for September 2007--News About Diet Drugs
	Rimonabant Found to Significantly Reduce Dangerous Abdominal Fat Sanofi Disappoints Dieters; Won't Try to Sell Acomplia in U.S. for Years Vernalis Reports 'Striking Weight Loss' for Diet Drug Similar to Rimonabant Taranabant, Competitor to Rimonabant, in Final Months of Clinical Trial
	Rimonabant News for August 2007--News About Diet Drugs
	Copies of Acomplia (Rimonabant) Being Sold Without Prescription in India Americans Will Not Be Able to Buy Rimonabant in U.S. Anytime Soon
	Rimonabant News for July 2007--News About Diet Drugs
	European Regulators Decide Rimonabant Should Remain on Market Study: Rimonabant May Reduce Obesity-Related Liver Damage Diet Drug Rimonabant Now Seen by Sanofi as Requiring Indefinite Use
	Rimonabant News for June 2007 -- News About Diet Drugs
	Sanofi Pulls U.S. Application for Sale of Diet Drug Acomplia (Rimonabant) Court: Sanofi's Diet Drug Acomplia Will Not Be Reimbursed in Germany Indian Pharmas: No Plans to Withdraw Rimonabant From the Market European Regulators to Review Safety Data for Sanofi's Acomplia FDA Panel Recommends Against Sale of Sanofi's Acomplia in U.S. Delay in U.S. Approval of Sanofi's Rimonabant Tied to Suicide, Seizures Vexing Month for Sanofi Over Rimonabant Likely to Peak in Week Ahead Sellers of Diet Drug Rimonabant Unfazed by Competition from Acomplia Acomplia (Rimonabant) Diet Pill Goes on Sale in United Arab Emirates Sanofi's Acomplia (Rimonabant) Widely Found in Mexican Pharmacies
	Rimonabant News for May 2007 -- News About Diet Drugs
	Added Health Claims for Diet Drug Rimonabant Questioned in Britain Do Indian Versions of Diet Drug Rimonabant Work the Same as Acomplia How Indian Pharmas Beat Sanofi to the Market With Diet Drug Rimonabant Sanofi 'Examining Options' Against Sellers Offering Generic Rimonabant 2nd Generic Version of Rimonabant (Acomplia / Zimulti) Hits Market in India Generic Version of Rimonabant (Acomplia / Zimulti) Launched in India Raids in Europe Crack Ring Selling Counterfeit Acomplia on the Internet
	Rimonabant News for April 2007 -- News About Diet Drugs
	Diet Drug Acomplia (Rimonabant) Approved for Sale in Brazil It's Official. Diet Drug Acomplia (Rimonabant) to Use Name Zimulti in U.S. Diet Drug Acomplia (Rimonabant) Approved for Sale in Switzerland Competitor for Diet Drug Rimonabant Now Has a Name: Taranabant
	Rimonabant News for March 2007--News About Diet Drugs
	Diet Drug Acomplia Concerns to Be Aired by FDA Advisory Panel in July Few in France to Get Reimbursement for Diet Drug Acomplia Diet Pill Acomplia Seen Becoming 'Gold Standard' for Treating Obesity Diet Drug Acomplia Now on Sale in Some Mexican Border Pharmacies
	Rimonabant News for February 2007-- News About Diet Drugs
	Diet Drug Acomplia Seen Unlikely to Get FDA OK for 'Metabolic Syndrome' Diet Pill Acomplia (Rimonabant) Hits New Three-Month Delay at U.S. FDA Diet Drug Acomplia Gets French OK Limited to Obese Diabetics Most Significant "Wait Loss" for Diet Drug Acomplia Is Loss of Sanofi Lead
	Rimonabant News for January 2007 -- News About Diet Drugs
	UK Company Plans Trial of Diet Drug With Same Target as Acomplia Diet Pill Rimonabant (Acomplia / Zimulti) Not Yet Available in Mexico Diet Drug Acomplia Rejected for Coverage by German Health Insurance Expert Says Overactive Endocannibanoid System May Be Key to Obesity
	Rimonabant News for Jan. to Dec. 2006 -- Click for 2006 News Achive
	Rimonabant News for Jan. to Dec. 2005 -- Click for 2005 News Achive
	Rimonabant News for Jan. to Dec. 2004 -- Click for 2004 News Achive

Other Diet Resources

Privacy Policy | Terms and Disclaimers | About the Rimonabant Report

Contact Us

We subscribe to the HONcode principles of the HON Foundation.

This is an independent news site reporting on Rimonabant, a diet drug developed by Sanofi-Aventis which markets it in Europe as Acomplia. Nothing on this site is intended to infringe on that trademark. Nothing on this site is intended as medical advice. The information provided here is for informational purposes only. Always consult a doctor or medical professional with questions you may have regarding a medical condition.

Last Updated: 05/04/2008